Skip to content

Bevacizumab

Avastin (bevacizumab) is an antibody pharmaceutical. Bevacizumab was first approved as Avastin on 2004-02-26. It is used to treat colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, and non-small-cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, non-small-cell lung carcinoma, and ovarian neoplasms amongst others. The pharmaceutical is active against vascular endothelial growth factor A.
Trade Name Avastin
Common Name Bevacizumab
ChEMBL ID CHEMBL1201583
Indication breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, peritoneal neoplasms, renal cell carcinoma, uterine cervical neoplasms
Drug Class Monoclonal antibodies: humanized, cardiovascular indications
Bevacizumab
Get full access now